skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 81  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Cognitive Function in a Randomized Trial of Evolocumab
Material Type:
Article
Add to My Research

Cognitive Function in a Randomized Trial of Evolocumab

The New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214

Full text available

2
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Material Type:
Article
Add to My Research

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2013-11, Vol.128 (19), p.2113-2120 [Peer Reviewed Journal]

2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.113.004678 ;PMID: 24014831 ;CODEN: CIRCAZ

Full text available

3
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Material Type:
Article
Add to My Research

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 24, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61374-X ;PMID: 25282520 ;CODEN: LANCAO

Full text available

4
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
Material Type:
Article
Add to My Research

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk

The American journal of cardiology, 2016, Vol.117 (1), p.40-47 [Peer Reviewed Journal]

The Authors ;2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jan 1, 2016 ;ISSN: 0002-9149 ;EISSN: 1879-1913 ;DOI: 10.1016/j.amjcard.2015.10.021 ;PMID: 26547291 ;CODEN: AJCDAG

Full text available

5
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Material Type:
Article
Add to My Research

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2211023 ;PMID: 36342163

Full text available

6
Inflammatory and Cholesterol Risk in the FOURIER Trial
Material Type:
Article
Add to My Research

Inflammatory and Cholesterol Risk in the FOURIER Trial

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]

2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884

Full text available

7
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
Material Type:
Article
Add to My Research

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]

2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113

Full text available

8
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Material Type:
Article
Add to My Research

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]

Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601

Full text available

9
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study
Material Type:
Article
Add to My Research

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study

Circulation Journal, 2014, Vol.78(5), pp.1073-1082 [Peer Reviewed Journal]

2014 THE JAPANESE CIRCULATION SOCIETY ;ISSN: 1346-9843 ;EISSN: 1347-4820 ;DOI: 10.1253/circj.CJ-14-0130 ;PMID: 24662398

Full text available

10
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure
Material Type:
Article
Add to My Research

Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure

Journal of the American Heart Association, 2020-08, Vol.9 (16), p.e015042-e015042 [Peer Reviewed Journal]

2020 The Authors, Amgen Inc, and Humana Inc. Published on behalf of the American Heart Association, Inc., by Wiley. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/jaha.119.015042 ;PMID: 32805181

Full text available

11
Apoptosis in neural development and disease
Material Type:
Article
Add to My Research

Apoptosis in neural development and disease

Annual review of neuroscience, 2000-01, Vol.23 (1), p.73-87 [Peer Reviewed Journal]

2000 INIST-CNRS ;Copyright Annual Reviews, Inc. 2000 ;ISSN: 0147-006X ;EISSN: 1545-4126 ;DOI: 10.1146/annurev.neuro.23.1.73 ;PMID: 10845059 ;CODEN: ARNSD5

Full text available

12
Apaf-1 Deficiency and Neural Tube Closure Defects are Found in fog Mice
Material Type:
Article
Add to My Research

Apaf-1 Deficiency and Neural Tube Closure Defects are Found in fog Mice

Proceedings of the National Academy of Sciences - PNAS, 2001-08, Vol.98 (17), p.9683-9687 [Peer Reviewed Journal]

Copyright 1993-2001 National Academy of Sciences of the United States of America ;Copyright National Academy of Sciences Aug 14, 2001 ;Copyright © 2001, The National Academy of Sciences 2001 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.171283198 ;PMID: 11504943

Full text available

13
오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
Material Type:
Patent
Add to My Research

오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법

Digital Resources/Online E-Resources

14
Methods of treating heart failure by administering omecamtiv mecarbil
Material Type:
Patent
Add to My Research

Methods of treating heart failure by administering omecamtiv mecarbil

Digital Resources/Online E-Resources

15
CARDIOVASCULAR BENEFIT OF EVOLOCUMAB IN 27,564 PATIENTS WITH AND WITHOUT AUTOIMMUNE OR INFLAMMATORY DISEASES: AN ANALYSIS OF THE FOURIER TRIAL
Material Type:
Article
Add to My Research

CARDIOVASCULAR BENEFIT OF EVOLOCUMAB IN 27,564 PATIENTS WITH AND WITHOUT AUTOIMMUNE OR INFLAMMATORY DISEASES: AN ANALYSIS OF THE FOURIER TRIAL

Journal of the American College of Cardiology, 2024-04, Vol.83 (13), p.1682-1682 [Peer Reviewed Journal]

2024 American College of Cardiology Foundation ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/S0735-1097(24)03672-6

Full text available

16
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Material Type:
Article
Add to My Research

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Circulation (New York, N.Y.), 2018-08, Vol.138 (8), p.756-766 [Peer Reviewed Journal]

2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034309 ;PMID: 29626068

Full text available

17
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Material Type:
Article
Add to My Research

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke (1970), 2020-05, Vol.51 (5), p.1546-1554 [Peer Reviewed Journal]

2020 American Heart Association, Inc. ;ISSN: 0039-2499 ;EISSN: 1524-4628 ;DOI: 10.1161/STROKEAHA.119.027759 ;PMID: 32312223

Full text available

18
METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS
Material Type:
Patent
Add to My Research

METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS

Digital Resources/Online E-Resources

19
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
Material Type:
Article
Add to My Research

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

The Lancet (British edition), 2016-12, Vol.388 (10062), p.2895-2903 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 10, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32049-9 ;PMID: 27914656 ;CODEN: LANCAO

Full text available

20
THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)
Material Type:
Article
Add to My Research

THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)

Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.667-667 [Peer Reviewed Journal]

2020 American College of Cardiology Foundation ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/S0735-1097(20)31294-8

Full text available

Results 1 - 20 of 81  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (32)

Refine My Results

Creation Date 

From To
  1. Before 2012  (3)
  2. 2012 To 2014  (5)
  3. 2015 To 2017  (18)
  4. 2018 To 2021  (34)
  5. After 2021  (22)
  6. More options open sub menu

Resource Type 

  1. Patents  (46)
  2. Articles  (35)
  3. More options open sub menu

Language 

  1. English  (71)
  2. French  (13)
  3. Japanese  (12)
  4. Spanish  (8)
  5. German  (3)
  6. Chinese  (3)
  7. Korean  (2)
  8. Portuguese  (2)
  9. Hebrew  (1)
  10. Arabic  (1)
  11. More options open sub menu

Searching Remote Databases, Please Wait